Finch has a portfolio of innovative microbiome assets
Finch, an early pioneer in the microbiome field, has established a portfolio of innovative microbiome assets with potential applicability to a wide range of product strategies and therapeutic areas. In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent C. difficile and focus on realizing the value of its IP estate and other assets.
Finch has established a leading portfolio of microbiome assets designed with insights from human microbiota transplantation studies.Learn more
Finch has a robust intellectual property estate reflecting the Company’s pioneering role in the microbiome therapeutics field.Learn more